Results 81 to 90 of about 26,568 (218)

Homophily‐adjusted social influence estimation

Canadian Journal of Statistics, EarlyView.
Abstract Homophily and social influence are two key concepts of social network analysis. Distinguishing between these phenomena is difficult, and approaches to disambiguate the two have been primarily limited to longitudinal data analyses. In this study, we provide sufficient conditions for valid estimation of social influence through cross‐sectional ...
Hanh T.D. Pham, Daniel K. Sewell
wiley   +1 more source

Mitigating measurement error in misspecified small area models

Canadian Journal of Statistics, EarlyView.
Abstract In the framework of Small area estimation, we consider an area‐level model where a subset of covariates is measured with error. The extent of the error is assumed to be constant throughout the areas, and it is expressed by a scalar parameter γ$$ \gamma $$, which multiplies the deterministic covariance matrix of the estimator of the true ...
Diego Battagliese, Serena Arima, Brunero Liseo, Alessio Pollice   +3 more
wiley   +1 more source

Z‐residuals diagnostics for Cox models: Functional‐form misspecification versus nonproportional hazards

Canadian Journal of Statistics, EarlyView.
Abstract Primary biliary cholangitis (PBC) is a progressive autoimmune cholestatic disease for which modelling death, with transplantation as a competing event, is clinically important. Cox proportional hazards (PH) models are widely used, but standard diagnostics detect lack of fit without distinguishing non‐PH from misspecified covariate functions ...
Tingxuan Wu, Cindy Feng, Longhai Li
wiley   +1 more source

AI‐Enabled Precision Dosing in Pediatrics: Enhancing Model‐Informed Decision Making

Clinical Pharmacology &Therapeutics, EarlyView.
Ensuring safe and effective pharmacotherapy for children remains a central challenge in clinical pharmacology, yet rapid advances in AI have not translated into clinical practice. This Perspective highlights how AI‐enabled approaches can enhance model‐informed decision making for precision dosing.
Kei Irie, Tomoyuki Mizuno
wiley   +1 more source

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann, Ruy M. Ribeiro, Aurelien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source

Model‐Informed Approaches for Pediatric Type 2 Diabetes Evidence Generation: Insights from a Model‐Based Longitudinal HbA1c Meta‐Analysis from EMA Marketing Authorization Applications

Clinical Pharmacology &Therapeutics, EarlyView.
Evidence generation for antihyperglycemic therapies in pediatric type 2 diabetes mellitus (T2DM) remains challenging, with most randomized trials failing to demonstrate statistically significant reductions in glycated hemoglobin (HbA1c), partly due to substantial between‐subject variability.
Pieter J. Colin, Efthymios Manolis, Jeroen V. Koomen   +2 more
wiley   +1 more source

Considerations for the Integration of Clinical Trials and Real‐World Data

Clinical Pharmacology &Therapeutics, EarlyView.
As clinical decision‐making increasingly moves toward individualized and context‐specific treatment recommendations, reliance on any single evidence source, randomized or observational, may be insufficient. Principled integration of randomized controlled trials and real‐world data, grounded in explicit causal frameworks, offers a path toward evidence ...
Sky Qiu, Charles E. Barr, Lauren Dang, Larry Han, Kajsa Kvist, Hana Lee, Andrew Mertens, Nerissa Nance, Lei Nie, Kara Rudolph, Xu Shi, Jens Tarp, Salina P. Waddy, Kenneth Wiley, Andy Wilson, Margot Lisa Jing Yann, Zhiwei Zhang, Tianyue Zhou, Maya Petersen, Mark van der Laan   +19 more
wiley   +1 more source

The EMA Qualification Opinion for CYP Inhibition‐Mediated Drug–Drug Interaction Predictions: Implications for PBPK Credibility Assessment in the Era of ICH M15

Clinical Pharmacology &Therapeutics, EarlyView.
Clinical pharmacology and pharmacometrics teams are now being encouraged to implement the ICH M15 framework in drug development to support model‐informed decisions in regulatory submissions. Although model performance is an important component of model evaluation, regulatory confidence also depends on the intended context of use (CoU) and the ...
Karen Rowland Yeo, Sibylle Neuhoff, Oliver Hatley, Iain Gardner, Céline Brochot, Frédéric Y. Bois, Masoud Jamei   +6 more
wiley   +1 more source

Bayesian Causal Inference for High-Dimensional Treatment Effect Estimation

Proceedings of the International Conference on Applied Innovations in IT
This paper presents a Bayesian framework for estimating individualized treatment effects (ITE) in high-dimensional observational data. The proposed approach integrates flexible Bayesian regression with neural-based outcome modeling to estimate ...
Saif Hosam Raheem
doaj   +1 more source

The AI Sustainability Paradox: How Verification and Regulation Synergize to Curb Greenwashing in Emerging Markets

Corporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT Artificial intelligence (AI) reflects a paradox for corporate sustainability: it provides tools for genuine socio‐economic improvement and enables greenwashing at scale. This study examines this duality in emerging Asian markets, where rapid AI adoption coincides with evolving regulatory regimes.
Ashutosh Yadav, Simplice A. Asongu
wiley   +1 more source